Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
Jevalikar G, Mithal A, Singh A, Sharma R, Farooqui KJ, Mahendru S, Dewan A, Budhiraja S
Scientific reports · 44 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-03-18 · Sci Rep · vol. 11 · número 1 · pág. 6258
- Editorial
- Nature Portfolio
- Citado
- 105 citas · más que el 100% de estudios similares · 14.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 37 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · Vitamin C and Antioxidants Research
- Palabras clave
- Medicine, Vitamin D and neurology, Internal medicine, Coronavirus disease 2019 (COVID-19), Gastroenterology, vitamin D deficiency, Cholecalciferol, Prospective cohort study, Severity of illness, Observational study, Ferritin, Disease
- MeSH
- humans, vitamin d deficiency, cholecalciferol, parathyroid hormone, vitamin d, severity of illness index, prevalence, prospective studies, cross-sectional studies, adolescent, adult, aged, aged, 80 and over, middle aged, child, india, female, male, young adult, covid-19
8 autores
- Ganesh Jevalikar🇮🇳 · autor de correspondenciaMax Healthcare
- Ambrish Mithal🇮🇳Max Healthcare
- Anshu Singh🇮🇳Max Healthcare
- Rutuja Sharma🇮🇳Max Healthcare
- Khalid Jamal Farooqui🇮🇳Max Healthcare
- Shama Mahendru🇮🇳Max Healthcare
- Arun Dewan🇮🇳Max Healthcare
- Sandeep Budhiraja🇮🇳Max Healthcare
Resumen
El texto original del estudio, en el idioma en que se publicó.
Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.